Indoleamine 2,3-dioxygenase

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO

Retrieved on: 
Thursday, April 27, 2023
Vaccine, CIN, Therapy, Virology, GV, 1994 expanded World Health Organization AIDS case definition, Cancer, Woman, Global health, Gilead, Human papillomavirus infection, Acquisition, Cervical cancer, Patient, SAN, Apoptosis, HPV, Knowledge, Diagnosis, Indoleamine 2,3-dioxygenase, Soteria, Health, MPM, Forty-seven rōnin, Pharmaceutical industry, Management

SOUTH SAN FRANCISCO, April 27, 2023 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $53 million Series E equity financing. The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company's existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others. In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company's board of directors and is being succeeded as CEO by Kristine Ball. Additionally, Ms. Ball, along with Florencia Segal, M.D., and Brian Goodman, Ph.D., both of MPM-BioImpact Capital, will join the Antiva board.

Key Points: 
  • The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company's existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others.
  • In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company's board of directors and is being succeeded as CEO by Kristine Ball.
  • Additionally, Ms. Ball, along with Florencia Segal, M.D., and Brian Goodman, Ph.D., both of MPM-BioImpact Capital, will join the Antiva board.
  • "I take great pride in turning the CEO role over to Kristine with the company in such a strong position following this transformative financing.

DGAP-News: MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

Retrieved on: 
Wednesday, October 20, 2021
Constellation, Safety, Disease, Autoantibody, BLA, Urine, Communication, Degenerative disease, Clinical trial, MM, Inflammation, Immune system, CD38, Incidence, Blood, Judgement, FSE, Interstitial lung disease, Food, U.S. Securities and Exchange Commission, Lymphoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Annual report, Autoimmune disease, Physician, Indoleamine 2,3-dioxygenase, China, Industry, Antibody, B cell, Chronic kidney disease, LLC, Lenalidomide, Risk, Patient, MD, Cancer, Immunoglobulin A, NASDAQ, Psoriasis, Janssen Pharmaceuticals, Kidney bean, Kidney, Asia, Multiple myeloma, Glomerulosclerosis, Pharmaceutical industry, IgAN, MorphoSys, IGAN, MORPHOSYS

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).
  • "Dosing of the first IgAN patient is an exciting milestone for MorphoSys, physicians and patients alike as we are rapidly broadening our development program for felzartamab."
  • Felzartamab (MOR202) is an investigational therapeutic human monoclonal antibody derived from MorphoSys' HuCAL(R) antibody library and directed against CD38.
  • By targeting CD38, felzartamab has the potential to deplete the CD38 positive plasma cells, which may ultimately improve the patient's kidney functions.

DGAP-News: Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

Retrieved on: 
Thursday, August 5, 2021
Company, MD, Lists of World Heritage Sites, Chief executive officer, Indoleamine 2,3-dioxygenase, Research, Industry, CSO, Ribonuclease H, ASO, Time, Database, LNA, Asos, Gene, Data, Drug discovery, Complementarity, Gene expression, RNA, Doctor of Philosophy, Therapy, Ribonuclease, Fine chemical, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG, SECARNA'S PROPRIETARY DRUG DISCOVERY PLATFORM, LNAPLUSTM, SECARNA PHARMACEUTICALS GMBH & CO. KG

The article, "Investigation of the activity of antisense oligonucleotides targeting multiple genes by RNA sequencing" was published in Nucleic Acid Therapeutics was published in Nucleic Acid Therapeutics: https://www.liebertpub.com/doi/10.1089/nat.2020.0932

Key Points: 
  • The article, "Investigation of the activity of antisense oligonucleotides targeting multiple genes by RNA sequencing" was published in Nucleic Acid Therapeutics was published in Nucleic Acid Therapeutics: https://www.liebertpub.com/doi/10.1089/nat.2020.0932
    Standard ASO design is based on the sequence complementarity of the oligo to its target.
  • However, the degree of target knockdown that ASOs can achieve varies strongly between different ASOs having full complementarity to the target.
  • In a first step, Secarna investigated the ASO's effectivity against IDO1.
  • Alexander Gebauer, MD, PhD, CEO and Managing Director of Secarna Pharmaceuticals, added: "At Secarna, we are constantly working on improving our proprietary LNAplusTM ASO therapies platform.

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

Retrieved on: 
Wednesday, July 14, 2021
Cancer treatments, Clinical medicine, Chemical compounds, Epacadostat, Oxadiazoles, Incyte, Indoleamine 2,3-dioxygenase, Cancer immunotherapy, Antineoplastic drugs, Breakthrough therapy, Pembrolizumab

The Phase I/IIa combination study is designed to evaluate BriaCells lead candidate, Bria-IMT, with Incytes checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.

Key Points: 
  • The Phase I/IIa combination study is designed to evaluate BriaCells lead candidate, Bria-IMT, with Incytes checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.
  • The BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates.
  • Under the agreement, Incyte is providing compounds from its development portfolio, including retifanlimab, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with Bria-IMT, in advanced breast cancer patients.
  • BriaCell and Incyte had previously treated two patients under this Phase I/IIa combination study subsequent to the corporate collaboration commencement in April 2019 .

ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline

Retrieved on: 
Wednesday, December 9, 2020
Clinical medicine, Medicine, Medical specialties, Immune system, Virotherapy, Cancer, Immunotherapy, Immune checkpoint, Prostate cancer, Tumor microenvironment, Indoleamine 2,3-dioxygenase

Evofosfamideis the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically cold tumors such as pancreatic & prostate cancer.

Key Points: 
  • Evofosfamideis the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically cold tumors such as pancreatic & prostate cancer.
  • Restoration of tumor oxygen supply facilitates T cell infiltration and persistence allowing these otherwise poorly immune checkpoint sensitive cancers to become therapeutically sensitized.
  • ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to catalyze effective immune responses in immunologically cold cancers such as prostate, colorectal, and pancreatic cancer.
  • These tumor types represent more than half of all cancers, and current immunotherapies have shown limited to no efficacy here.

DGAP-News: Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Retrieved on: 
Thursday, March 26, 2020
Amino acids, Branches of biology, Medicine, Immune system, Indoleamine 2,3-dioxygenase, Oncology, Cancer treatments, Signal transduction, Cancer immunology, Epacadostat, Immunotherapy, MTOR, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication

Key Points: 
  • DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
    Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
    The issuer is solely responsible for the content of this announcement.
  • Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
  • Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
  • The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.

Checkpoint Inhibitors: Global Markets

Retrieved on: 
Thursday, October 18, 2018
Medicine, Immune system, Clinical medicine, Immunology, Pembrolizumab, Checkpoint inhibitor, Ipilimumab, Indoleamine 2,3-dioxygenase, Programmed cell death protein 1, Melanoma, Monoclonal antibody, Immune checkpoint

In 2011, Bristol

Key Points: 
  • In 2011, Bristol
    Myers Squibb's Yervoy a CTLA-4 inhibitor became one of the first checkpoint inhibitor to be approved in the treatment of metastatic melanoma, despite considerable safety and tolerability concerns.
  • It took a further 3 years before the next checkpoint inhibitor Keytruda, a PD-1 inhibitor was approved for the treatment of advanced unresectable melanoma.
  • and immunometabolic enzymes Indoleamine 2,3-dioxygenase-1 (IDO-1) which utilize an array of innovative delivery technologies such as small molecule agents, monoclonal antibodies, bispecific antibodies and fusion proteins to target inhibit checkpoint proteins.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.